Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A6 | Q3KNW5 | 2/20 | 0.56 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.56 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 10/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.51 |
| ▸ | LMNA | P02545 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | HTT | P42858 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7120571 | 0.85 | SMN1; SMN2 (0.65) | SLC10A6SLC10A2SLC10A1MEN1KMT2A | |
| SCHEMBL492766 | 0.85 | SLC10A2 (0.52) | SLC10A6SLC10A2SLC10A1MEN1KMT2A | |
| SCHEMBL492769 | 0.85 | SLC10A2 (0.52) | SLC10A6SLC10A2SLC10A1MEN1KMT2A | |
| SCHEMBL491809 | 0.85 | ALDH1A1 (0.51) | MEN1KMT2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL27561779 | 0.85 | SLC10A6 (0.50) | SLC10A6SLC10A2SLC10A1MEN1KMT2A | |
| SCHEMBL7214479 | 0.83 | SLC10A6 (0.72) | SLC10A6SLC10A2SLC10A1MEN1KMT2A | |
| SCHEMBL10252896 | 0.83 | ALDH1A1 (0.58) | SLC10A6SLC10A2SLC10A1MEN1KMT2A | |
| Ataciguat SCHEMBL491675 | 0.82 | KMT2A (0.64) | MEN1KMT2ALMNAMAPTSMN1; SMN2 | |
| Ataciguat SCHEMBL29370450 | 0.82 | KMT2A (0.64) | MEN1KMT2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL7213170 | 0.81 | MEN1 (0.76) | SLC10A6SLC10A2SLC10A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2207541-B1 | USE OF SULFONYL-SUBSTITUTED 2-SULFONYLAMINOBENZOIC ACID N-PHENYLAMIDES IN THE TREATMENT OF PAIN | SANOFI AVENTIS DEUTSCHLAND (DE) | 2014-10-29 | — | — | EP | disclosed |
| US-8541410-B2 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8518998-B2 | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-08-27 | — | — | US | disclosed |
| US-20120108573-A1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH | 2012-05-03 | — | — | US | disclosed |
| US-8106213-B2 | For example, 2-(4-chloro-phenylsulfonylamino)-4,5-dimethoxy-N-(4-(thiomorpholine-4-sulfonyl)-phenyl)-benzamide; for therapy and prophylaxis of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20110021505-A1 | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2207541-A1 | USE OF SULFONYL-SUBSTITUTED 2-SULFONYLAMINOBENZOIC ACID N-PHENYLAMIDES IN THE TREATMENT OF PAIN | Sanofi-Aventis Deutschland GmbH (DE) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009043495-A1 | USE OF SULFONYL-SUBSTITUTED 2-SULFONYLAMINOBENZOIC ACID N-PHENYLAMIDES IN THE TREATMENT OF PAIN | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-04-09 | — | — | WO | disclosed |
| US-20080096936-A1 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | TELEVOX SOFTWARE, INCORPORATED | 2008-04-24 | — | — | US | disclosed |
| US-7326789-B2 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-05 | — | — | US | disclosed |
| EP-1614678-A2 | Sulfur substituted sulfonylaminocarboxylic acid N-heteroarylamides, their preparation, their use and pharmaceutical preparations comprising them | Sanofi-Aventis Deutschland GmbH (DE) | 2006-01-11 | — | — | EP | disclosed |
| EP-1095016-B1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI AVENTIS DEUTSCHLAND (DE) | 2005-11-09 | — | — | EP | disclosed |
| US-6881735-B2 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-04-19 | — | — | US | disclosed |
| US-20040186145-A1 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH. | 2004-09-23 | — | — | US | disclosed |
| US-20020061887-A1 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2002-05-23 | — | — | US | disclosed |
| US-6335334-B1 | HYPERTENSIVE AGENTS, ANTICOAGULANTS; CARDIOVASCULAR AND SEXUAL DISORDERS, ANGINA PECTORIS, AND ATHEROSCLEROSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-01-01 | — | — | US | disclosed |
| EP-1095016-A1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | Aventis Pharma Deutschland GmbH (DE) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000002851-A1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108573-A1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | GUCY1A1, GUCY1B1, GUCY1A2 | SLC10A6 1785/4885SLC10A2 2103/4885SLC10A1 1054/4885 |
| US-20110021505-A1 | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SCN1A, SCN2A, CACNA1A | SLC10A6 192/4885SLC10A2 422/4885SLC10A1 206/4885 |
| US-20040186145-A1 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | GUCY1A1, GUCY1B1, GUCY1A2 | SLC10A6 2557/4885SLC10A2 2365/4885SLC10A1 1586/4885 |
| US-20020061887-A1 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | GUCY1A1, GUCY1B1, GUCY1A2 | SLC10A6 2557/4885SLC10A2 2365/4885SLC10A1 1586/4885 |
| US-20080096936-A1 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | GUCY1A1, GUCY1A2, GUCY1B1 | SLC10A6 1841/4885SLC10A2 2189/4885SLC10A1 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.